Actively Recruiting
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
Led by National Cancer Institute (NCI) · Updated on 2026-05-13
65
Participants Needed
13
Research Sites
290 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This phase II trial studies the effects of combination therapy with bevacizumab, erlotinib, and atezolizumab in treating patients with hereditary leiomyomatosis and kidney cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Bevacizumab is in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumors. This may slow the growth and spread of tumors. Erlotinib is in a class of medications called kinase inhibitors. It works by blocking the action of a protein called EGFR that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Combination therapy with bevacizumab, erlotinib, and atezolizumab may stabilize or shrink advanced hereditary leiomyomatosis and kidney cancer.
CONDITIONS
Official Title
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of hereditary leiomyomatosis and renal cell cancer with confirmed renal cell carcinoma or confirmed sporadic papillary renal cell carcinoma
- Advanced renal cell cancer with measurable disease meeting specified size criteria
- No more than two prior VEGF-targeting regimens and no prior bevacizumab or PD-1/PD-L1 inhibitor therapy for advanced disease
- Age 12 years or older
- ECOG performance status of 0, 1, or 2 (Karnofsky score of 60% or higher)
- Adequate blood counts and liver function within specified limits
- Glomerular filtration rate (GFR) of at least 30 mL/min/1.73 m2 with creatinine thresholds for pediatric patients
- Controlled HIV, hepatitis B, or hepatitis C infection as specified
- Treated brain metastases stable for at least 3 months
- No prior or concurrent invasive malignancy likely to interfere with study
- Cardiac function classified as New York Heart Association class 2B or better
- Agreement to use effective contraception during and for 6 months after treatment
- Ability to provide tumor tissue samples or consent to biopsy
- Ability to understand and sign informed consent or have a legally authorized representative
You will not qualify if you...
- Prior systemic therapy for kidney cancer within 4 weeks or 5 half-lives before treatment start
- Radiotherapy for kidney cancer within 2 weeks before treatment
- Major surgery within 28 days before treatment start with unhealed wounds
- Unresolved toxicities from prior cancer treatments above grade 1 except alopecia or correctable electrolyte abnormalities
- Recent treatment with other investigational agents, systemic immunostimulants, or immunosuppressive medications within specified timeframes
- Uncorrected hypercalcemia and use of bisphosphonates for symptomatic hypercalcemia
- History of autoimmune diseases except stable autoimmune hypothyroidism, controlled type 1 diabetes, or certain skin conditions
- History of lung diseases including pneumonitis or active pneumonitis
- Untreated latent or active tuberculosis
- Severe infections requiring hospitalization within 4 weeks before treatment
- Recent live attenuated vaccine within 4 weeks before treatment or planned during study
- Uncontrolled illnesses including infections, heart failure, unstable angina, arrhythmia, or psychiatric conditions
- Poorly controlled hypertension despite treatment
- Prior bone marrow or solid organ transplant
- Severe allergic reactions to similar drugs
- Recent major cardiovascular or gastrointestinal events within 6 months
- Significant proteinuria exceeding specified thresholds
- Pregnancy or breastfeeding
- Serious non-healing wounds, ulcers, or recent bone fractures
- Use of strong CYP450 inhibitors or inducers
- Inability to stop tobacco or nicotine use during treatment
- Significant vascular disease or recent bleeding disorders
- Recent use of high-dose aspirin or clopidogrel except stable therapeutic anticoagulation or prophylactic anticoagulants allowed
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 13 locations
1
UC San Diego Moores Cancer Center
La Jolla, California, United States, 92093
Actively Recruiting
2
Emory University Hospital Midtown
Atlanta, Georgia, United States, 30308
Actively Recruiting
3
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, United States, 30322
Actively Recruiting
4
Emory Saint Joseph's Hospital
Atlanta, Georgia, United States, 30342
Actively Recruiting
5
Northwestern University
Chicago, Illinois, United States, 60611
Actively Recruiting
6
National Institutes of Health Clinical Center
Bethesda, Maryland, United States, 20892
Suspended
7
NCI - Center for Cancer Research
Bethesda, Maryland, United States, 20892
Actively Recruiting
8
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States, 08903
Actively Recruiting
9
NYU Langone Hospital - Long Island
Mineola, New York, United States, 11501
Active, Not Recruiting
10
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York, United States, 10016
Active, Not Recruiting
11
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States, 43210
Actively Recruiting
12
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, United States, 15232
Actively Recruiting
13
M D Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here